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ABSTRACT:
myc genes are associated with a wide variety of human cancers including most types 
of nervous system tumors. While the mechanisms by which myc overexpression causes 
tumorigenesis are multifaceted and have yet to be clearly elucidated, they are at least 
in part related to endogenous myc function in normal cells. Knockout (KO) of either 
c-myc or N-myc genes in neural stem and precursor cells (NSC) driven by nestin-cre 
impairs mouse brain growth and mutation of N-myc also causes microcephaly in humans 
in  Feingold  Syndrome.  To  further  define  myc  function  in  NSC  and  nervous  system 
development, we created a double KO (DKO) for c- and N-myc using nestin-cre. The 
DKO mice display profoundly impaired overall brain growth associated with decreased 
cell cycling and migration of NSC, which are strikingly decreased in number. The DKO 
brain also exhibits specific changes in gene expression including downregulation of 
genes involved in protein and nucleotide metabolism, mitosis, and chromatin structure 
as well as upregulation of genes associated with differentiation. Together these data 
support a model of nervous system tumorigenesis in which excess myc aberrantly locks 
in a developmentally active chromatin state characterized by overactive cell cycling, 
and metabolism as well as blocked differentiation.
INTRODUCTION
myc is well-known for its role in tumorigenesis when 
overexpressed  and  N-myc  (MYCN)  is  most  strongly 
associated with primitive “blast” nervous system tumors 
neuroblastoma,  medulloblastoma,  retinoblastoma,  and 
glioblastoma [1-11]. However, at physiological levels myc 
genes are important regulators of many aspects of normal 
cell behavior including metabolism and cycling (reviewed 
in [12]). myc genes encode members of the basic-helix-
loop-helix zipper (bHLHZ) transcription factor superfam-
ily, but Myc proteins are very atypical bHLHZ factors in the 
diversity of their functions. They can activate and repress 
the transcription of specific protein coding genes, influence 
expression of miRNA and rRNA, drive DNA synthesis, and 
globally influence chromatin structure. More recently myc 
has been shown to relieve transcriptional pausing in embry-
onic  stem  cells  (ESC)  through  a  mechanisms  involving 
PTEF-b [13], but in many cases the mechanisms by which 
myc achieves its diversity of functions are not well under-
stood. One theory is that Myc’s wide range of functions is 
linked to its widespread euchromatic function associated 
with specific histone modifications such as acetylation of 
lysine 9 and methylation of lysine 4 of histone H3 [14-19].
There is growing evidence of key roles for myc genes at 
endogenous levels in both somatic stem cells such as NSC 
and ESC. Constitutive knockout (KO) of c-myc or N-myc 
causes embryonic lethality around midgestation [20, 21]. 
Conditional disruption of N-myc in NSC severely disrupts 
murine brain growth, particularly that of the cerebellum, 
while a similar KO of c-myc moderately impairs growth 
[22, 23]. Disruption of either c-myc or N-myc or both in 
hematopoietic stem cells (HSC) also alters their normal 
biological  functions,  affecting  survival  and  self-renewal 
[24, 25]. myc genes also are involved in the production of 
induced pluripotent stem (iPS) cells (reviewed in [26]) [27-
31]. While exogenous myc is not formally required for the 
process [32, 33], it dramatically enhances the efficiency and 121
in its absence its function is likely supplanted by endog-
enous myc. During iPS cell formation, Myc represses dif-
ferentiation-associated genes [34] and may not have a key 
role in directly maintaining expression of pluripotency fac-
tors. However, in neuroblastoma some pluripotency genes 
such as lif, lin28b, Klf2, and Klf4 are N-Myc targets for 
activation, while a subset of these genes is also regulated 
in NSC by N-myc [35]. Another role that Myc may play in 
pluripotency is maintenance of the high levels of cellular 
metabolism, including protein (reviewed in [37]) and DNA 
[38] synthesis, observed in highly pluripotent cells.
Perhaps  because  of  the  importance  of  myc  genes  in 
normal cellular biology and their ability to cause cancer 
when in excess, cells have evolved systems to maintain 
normal total cumulative myc RNA and Myc protein levels. 
These include cross-regulation, redundancy and compensa-
tion between the 3 main myc genes – c-, N-, and L-myc – as 
well as myc-trigged apoptosis when in excess. Myc pro-
tein stability is also tightly controlled (reviewed in [39]). 
Conditional double knockout (DKO) of c- and N-myc in 
hematopoietic stem cells yields a far more severe pheno-
type than disruption of either gene alone, suggesting addi-
tive or redundant roles [25]. A large degree of redundancy 
is also supported by the knockin of N-myc into the c-myc 
locus largely rescuing the loss of c-myc [40]. The prevail-
ing theory is that what is most critical is the total level of all 
myc gene expression in each cell. Despite fairly ubiquitous 
expression in the developing brain and some other regions 
of the embryo, L-myc constitutive KO was reported to have 
no phenotype at all [41]. One notion is that this lack of 
apparent phenotype was due to the continued presence of 
N-myc and perhaps c-myc, which could fulfill the roles of 
L-myc in its absence.
During neurogenesis, N-myc plays a particularly impor-
tant role in NSC to direct brain growth and development 
[22, 42], consistent with its fairly widespread expression 
pattern. N-myc is also essential for normal eye and neural 
retina development [43, 44]. L-myc is also fairly widely 
expressed, particularly in the early midbrain, which sug-
gests  it  may  function  in  the  brain  despite  no  reported 
KO phenotype. Although c-myc expression has been less 
clearly defined, it appears to be more restricted than that of 
L- and N-myc. Overexpression and c-myc KO studies in rat 
neurospheres support a crucial role for myc genes overall 
in NSC function and suggested functional ties to p53/Arf 
[45], but the relevance for in vivo neurogenesis and tumori-
genesis remains unclear. The molecular basis of the c- and 
N-myc nestin-cre driven brain phenotypes is also not com-
pletely clear, but in the N-myc knockout changes in cyclin 
D2 and cyclin dependent kinase inhibitors such as p18 and 
p27 were evident suggesting cell cycle regulation plays a 
role [22, 46], including in the cerebellum.  Impeding our 
understanding is the fact that no unbiased global analysis of 
gene expression has been conducted for any Myc transcrip-
tion factors using a loss of function model in the nervous 
system. Upstream of N-myc are several potential signaling 
pathways including Shh in the cerebellum and in cerebellar 
granule neural progenitors (CGNP) [23, 47], while N-myc 
also appears to be a critical part of a recently defined path-
way DLL3 and Notch signaling in which N- Myc protein is 
targeted by the Huwe1 ubiquitin ligase [11, 48]. 
To address the endogenous functions of c- and N-myc 
in  brain  growth,  we  created  a  nervous  system  specific 
double c- and N-myc KO (DKO) mouse by crossing doubly 
homozygously myc floxed mice with nestin-cre, which is 
expressed specifically in NSC. The myc DKO mice have 
a nervous system phenotype much more severe than either 
single myc KO alone, which is ultimately lethal. In terms of 
mechanisms underlying the phenotype, we found evidence 
that myc transactivates key gene expression programs in 
NSC including that of metabolic genes essential for normal 
stem  and  precursor  fate  during  neurogenesis,  chromatin 
regulatory  genes,  and  mitosis-related  genes.  In  addition 
myc appears to repress expression of genes associated with 
differentiation.  Together these findings support the model 
that excess myc causes nervous system tumors by “lock-
ing in” a chromatin-based developmental program in NSC 
characterized by rapid cell cycling, high cellular metabo-
lism, and blocked differentiation.
RESULTS
Double knockout (DKO) of c- and N-myc in NSC 
driven by nestin-cre causes a striking impairment of 
embryonic brain growth
Control (c-myc flox/flox; N-myc flox/flox) and DKO 
(c-myc flox/flox; n-myc flox/flox nestin-cre+) embryos were 
produced by timed matings. Embryonic brains were iso-
lated at different stages and analyzed. At E14.5, embryonic 
brains were microdissected into fore-, mid-, and hindbrains 
followed by RNA isolation. q RT-PCR was conducted for 
c- and N-myc.  All three main regions of the embryonic 
brain exhibited pronounced decreases in expression of both 
myc genes. c- and N-myc levels were reduced by approxi-
mately 20 and 50-fold in the forebrain, 40 and 20-fold in 
the midbrain, and 15 and almost 100-fold in the hindbrain, 
respectively (Fig. 1A). In terms of phenotype, the E17.5 
brain overall was dramatically reduced in size, particularly 
in the forebrain/neocortex (Fig. 1B). The DKO hindbrain 
also exhibited a growth phenotype, albeit somewhat less 
severe at this stage. Surprisingly, the growth of the DKO 
midbrain was not significantly affected despite the strong 
reductions in c- and N-myc therein, suggesting midbrain 
growth prior to midgestation is largely independent of c- 
and N-myc.  In support of this notion, the DKO adult mid-
brain was also largely normal (not shown).
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Figure 1. Nestin-Cre mediates potent reductions in both c- and N-myc expression levels through-
out the brain causing dramatically impaired growth of the fore- and hindbrain, but not the mid-
brain. (A) q RT-PCR for c- and N-myc expression. RNAs isolated from microdissected E17.5 control 
(N=4) and DKO (N=3) fore-, mid-, and hindbrains were used for q RT-PCR. Error bars are standard 
deviations. Mean levels in controls were set as 1.0. Median values are indicated by horizontal bars within 
vertical rectangles representing the range. p values were < 0.005 in each case. (B) Nissl stained E17.5 
sagittal sections of doubly homozygously floxed littermate control and DKO (doubly homozygously floxed 
nestin-cre+). Boxed regions are shown at higher magnification in Fig. 2A.
myc family expression patterns in the embryonic brain 
correlate with the general domain specificity of myc 
knockout phenotypes
We  have  previously  observed  high  levels  of  N-Myc 
protein expression in the developing forebrain and hind-
brain/cerebella [22]. These findings correlated with E15.5 
data from the brain gene expression website: http://www.
stjudebgem.org/web/mainPage/mainPage.php  (Supple-
mental Fig. S1). While c-myc expression at the protein or 
RNA levels is difficult to detect, there are hints of low-level 
expression in a number of regions including the develop-
ing cortex. N-myc is fairly ubiquitously expressed, but with 
relatively  lower  or  absent  expression  in  some  midbrain 
regions and very high levels in the neocortex and the devel-
oping cerebellum. L-myc, despite no reported KO pheno-
type,  has  particularly  high  expression  in  the  ventricular 
zone (VZ) of the embryonic midbrain supporting the notion 
that L-myc may be the central driver of midbrain develop-
ment, potentially explaining the absence of any clear mid-
brain phenotype in the c- and N-myc DKO.
Expression of c- and N-myc in NSC is essential for 
normal architecture of the late embryonic cortical 
wall.  
Because the DKO E17.5 cortex exhibited a dramatic 
overall phenotype visible to the eye, we examined it fur-
ther by microscopic histological analysis of Nissl stained 
sagittal sections (Fig. 2A). The DKO cortical wall has a 
number  of  phenotypic  characteristics  including  reduced 
overall thickness. Also evident was a hypocellular VZ and 
an apparent near complete absence of subventricular zone 
(SVZ; brackets in the floxed control) cells. These data sug-
gest very few precursors are migrating through and out 
of the SVZ in the DKO, however the cortical plate at this 
stage is only modestly reduced in number and not at all 
in thickness. Together these findings suggest precocious 
formation of the cortical plate earlier than normal during 
differentiation.
Loss of c- and N-myc strongly reduces cell cycling, 
especially mitosis in the SVZ.
To examine the potential effects of the myc DKO on cell 
cycling we stained for BrdU for S phase cells and phos-
phoH3 for M phase cells. The DKO cortical wall exhibited 
a pronounced decrease in the percentage of M phase cells 
(Fig. 2B), approximately 2-fold in the SVZ and 30% in 
the VZ (Figs. 2C-D). The more pronounced loss of mitotic 
cells in the SVZ is consistent with the notion of decreased 
migrating progenitors suggested by the Nissl staining. The 
absolute number of mitotic cells was even more dramati-
cally decreased given the hypocellularity of the DKO corti-
cal wall. We also observed a statistically significant loss of 
BrdU+ cells at all stages examined including as early as 
E12.5 (Supplemental Fig. S2A, Fig. 2E) and at E17.5. 
Loss of c- and N-myc alters cell fate in the SVZ and 
VZ, consistent with a substantial decrease in stem and 
progenitors.
To examine the identity of cells in the cortical wall, we 
stained for 4A4 (a marker of stem and progenitors) and 
neural specific B-tubulin III (TUJ) in control and DKO sec-
tions (Fig. 3). The absolute size of the TUJ+ subdomain was 
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not substantially altered in the DKO at E14.5 or at E17.5. 
However,  because  the  overall  cortical  wall  was  greatly 
reduced in thickness in the DKO, the relative proportion 
of the wall that was TUJ+ was strikingly increased in the 
DKO (E17.5, not shown; E14.5, Supplemental Fig. S4). 
Supporting the notion of reduced progenitors, particularly 
those that are migrating, we saw decreased 4A4+ cells in 
the DKO (Fig. 3). The decrease in 4A4+ stem and precur-
sor cells was not due to impaired cell survival as TUNEL 
staining indicated no clear different in apoptosis between 
control and DKO at E17.5 or at E12.5 (Supplemental Fig. 
S5; not shown). Interestingly, we found that while anti-
4A4 (phospho vimentin) most brightly stains basal stem/
precursors immediately adjacent within the VZ, cells in the 
TUJ- regions of the SVZ  also stained 4A4+ (albeit with 
only moderately intense staining). Such staining is nearly 
completely absent from the DKO (Fig. 3 bottom). Thus, the 
SVZ DKO cells are both TUJ and 4A4 negative as well as 
mostly negative for S and M phase of the cell cycle, sug-
gesting that they are in an abnormal developmental state 
and location due to the loss of myc.
c- and N-myc maintain expression of genes involved in 
most aspects of cellular metabolism, chromatin regula-
tory factors, and mitosis.
To  explore  the  mechanisms  by  which  Myc  proteins 
acting as transcription factors could regulate brain devel-
Figure 2. Loss of c- and N-myc disrupts cortical wall development with a particularly pronounced 
affect on the SVZ.  (A) Nissl stained E17.5 sagittal sections of cortical wall. Brackets indicate the normal 
SVZ, largely absent in the DKO. (B) Immunostaining for the mitotic marker phospho-H3 (green) in control 
and DKO E17.5 sections. Large and small brackets indicate SVZ and VZ respectively. (C) and (D) Quanti-
fication of percent mitotic/phosphoH3+ cells in the SVZ and VZ. (E) Quantification of S phase/BrdU+ cells 
in the entire cortical wall in control and DKO. Error bars are standard deviations. P values are indicated.
Figure 3. c- and N-myc are required to maintain normal NSC 
cell cycling in the forebrain. E17.5 Sagittal sections of control 
and myc DKO cortical walls were stained with TUJ (green), 4A4 
(red) and DAPI (blue). 40x magnification.
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opment and specific NSC functions such as cell cycling 
and fate, gene expression array studies were conducted on 
RNAs isolated from E17.5 control and DKO subdomains 
of the brain including forebrain, midbrain, and hindbrain/
cerebellum (Fig. 4). Whole brains were first isolated from 
E14.5-P21 to compare overall severity of phenotypes (Fig. 
4A-D). A phenotype was apparent as early as E12.5 and 
became  progressively  more  severe.  Interestingly,  while 
tangential growth of the brain was only modestly reduced, 
rostro-caudal growth was severely impaired at all stages. 
Forebrain,  midbrain,  and  hindbrain  were  microdissected 
from control (4 biological replicates) and DKO (3 biologi-
cal replicates), RNA was produced, and used to probe pro-
moter expression arrays (Fig. 4E-F). There was substantial 
overlap in the specific genes whose expression was altered 
in the DKO in the 3 domains, suggesting some conserved 
transcription functions for Myc in different subdomains of 
the brain. The magnitude of gene expression changes (total 
# of genes with increased or decreased expression) not sur-
prisingly was directly linkable to the severity of the phe-
notype in a given domain. For example, midbrain, which 
exhibits little if any phenotype had far fewer expression 
changes. Interestingly no two domains were more similar 
to each other than the third, suggesting that although the 
midbrain had no obvious outward phenotype and relatively 
fewer gene expression changes, a loss of myc gene expres-
sion midbrain phenotype was occurring to some extent.
In addition to examining specific genes, complete lists 
Figure 4. myc DKO whole brain and gene expression pheno-
types. Brains of indicated genotypes (DKO and littermate doubly 
floxed  cre  negative  controls)  were  microdissected  and  photo-
graphed from above (A-D). For expression microarrays, RNA was 
isolated from the indicated domain (fore, mid, or hindbrain; blue, 
green, and red respectively) in biological triplicate (DKO) or qua-
druplicate (control, doubly floxed Cre-). (E-F) Venn diagrams indi-
cate the number of genes whose expression was changed 1.3 fold 
or more in the indicate domain and the overlap.
Cluster Category P-Value
Forebrain
Ribosome 5.0 x 10-13 
Nucleoside biosynthesis  8.1 x 10-4
Midbrain
Actin  4.8 x 10-4 
Hindbrain
Ribosome 1.2 x 10-32 
Chromosomal part  1.2 x 10-8 
Nucleolus  4.8 x 10-8 
DNA metabolism  2.9x 10-7 
Mitosis  1.6 x 10-6 
Table 1. Ontology of genes downregulated in DKO
Table 2. Ontology of genes upregulated in DKO
Cluster Category P-Value
Forebrain
Signal  4.9 x 10-11 
Branching morphogenesis  1.4 x 10-6 
Cell Migration 3.2 x 10-6 
Pattern Specification  1.9 x 10-5 
Tube Development  4.4 x 10-5 
Extracellular structure  4.7 x 10-5 
Embryonic Organ Development  8.9 x 10-5 
Midbrain
Homeobox  3.6 x 10-4
Hindbrain
Glycoprotein  9.3 x 10-38 
Extracellular Matrix 4.2 x 10-34 
Vascular Development  4.2 x 10-16 
Tube Development  1.1 x 10-12 
Cell Adhesion  1.1 x 10-11 
Collagen  2.8 x 10-9 
Heart morphogenesis  8.3 x 10-8 
EGF-like region  8.5 x 10-8 
Polysaccharide binding  1.0 x 10-6 
Neurotransmitter transport  1.5 x 10-6
Fibronectin type III  2.7 x 10-5 
Wnt signaling  1.2 x 10-5 
Pattern Specification  3.3 x 10-5 
Neuron differentiation  3.5 x 10-5 
Hedgehog signaling  7.5 x 10-5 
Bone Development  8.6 x 10-5
Cell motion  1.4 x 10-4 
Ion Transport  3.3 x 10-4 
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of up or downregulated gene were subjected to ontologi-
cal  analysis  to  look  for  clusters  of  functionally  related 
genes that are changed by loss of myc using the DAVID 
algorithm  (http://david.abcc.ncifcrf.gov/).    Focusing  first 
on the candidate positively regulated Myc targets (genes 
downregulated in the DKO), the top scoring clusters were 
functionally related to ribosome biogenesis, protein trans-
lation, cellular metabolism, chromosomal binding proteins, 
and interestingly mitosis (Table 1). Of specific genes whose 
expression was altered by the DKO, most were verifiable 
by conventional RT-PCR and qRT-PCR (Supplemental Fig. 
S5A-B) and several downregulated genes, including Rpl23 
and Bcat1 [50], are known myc target genes. 
Loss of myc leads to gene expression signatures of 
differentiation including ontological clusters of genes 
involved in patterning, morphogenesis, migration, and 
neurogenesis.
There were many more genes upregulated by loss of 
myc than downregulated and correspondingly more func-
tional ontological clusters (Table 2). Of the upregulated 
genes in the DKO, ontological analysis suggested that Myc 
most  prominently  repressed  expression  of  genes  associ-
ated with differentiation during neurogenesis and that in 
the DKO differentiation was occurring inappropriately at 
E17.5  in cells that would otherwise have remained NSC. 
Interestingly, we also found pronounced upregulation of 
a number of Wnt family members in the myc DKO hind-
brain and N-myc has recently been implicated in cortical 
basal progenitors as a key effector of Wnt signaling [51]. 
The upregulation of Wnt signaling with loss of myc could 
reflect Myc repression of Wnt signaling in a negative feed-
back loop or alternatively be an indirect consequence of 
differentiation.
A subset of genes are consistently altered throughout 
the brain by loss of myc.
 
When  comparing  the  genes  whose  expression  was 
changed in the 3 domains of the brain by loss of myc, it is 
important to note that a significant number had increased or 
decreased expression in all 3 domains (Supplemental Fig. 
S6). These genes therefore have the strongest link with myc 
in overall brain development. Amongst the shared down-
regulated genes (putative positively Myc regulated genes), 
although  many  are  non-annotated,  ontological  analy-
sis indicates that there are 3 kinases (Pkm2, Mapk8, and 
Adk, p value = 0.07) and 9 genes involved in metabolism 
(includes the 3 kinases mentioned above plus Arbp, Usp29, 
Atp6v1d, Ptpre, and Picalm, p value = 0.04), suggesting 
key Myc targets in precursors are involved in signaling and 
cell metabolism. Of the shared genes upregulated (putative 
Myc suppressed genes), ontological analysis found cellular 
receptors (p value = 0.01), mostly associated with differen-
tiation including Wnt5a. Wnt signaling more generally was 
also upregulated specifically in the cerebellum, suggesting 
Myc may not only be a downstream effector of Wnt, but 
also regulate Wnt expression.
DISCUSSION
Although we and others have found very widespread 
chromatin and transcriptional functions for Myc proteins 
[15, 16, 19, 52-55], in our expression array studies here 
on control and myc DKO brain tissues, we found relatively 
modest levels of changes in gene expression and in some 
domains relatively few genes had altered expression with 
loss of myc. This is somewhat surprising given the striking 
severity of the DKO phenotype, but it may be reflective of 
the complexity of cell types in the developing brain (even 
when divided into fore-, mid-, and hindbrain) compared 
to more homogeneous cell lines used in previous studies. 
Nonetheless specific patterns of changes clearly emerged 
from ontological analyses.  We observed that a key function 
for myc in NSC in the developing brain is to maintain over-
all cellular metabolism with particularly important roles in 
ribosome biogenesis and nucleotide metabolism. 
We also observed an ontological cluster of downregu-
lated mitotic genes that was highly significant, supporting a 
potential novel role for myc in regulating mitosis of normal 
NSC. Remarkably no mitotic genes were upregulated by 
loss  of  Myc.  Recently  Myc-induced  genomic  instability 
has been shown to be due to at least in part to mitotic dys-
function [56], consistent with our findings, and together 
suggesting normal Myc levels, not too high or too low, 
are essential for mitosis. Since we have also previously 
observed  abnormal,  widespread  chromatin  changes  with 
loss of myc in NSC [16], this altered chromatin state may 
in addition contribute to problems going through mitosis 
in myc DKO NSC due to premature chromatin condensa-
tion in G2 or to failure to decondense late during mitosis. 
We also observed a decrease in mitotic cells throughout the 
developing DKO brain ranging from 50% to 2-fold depend-
ing on the region, but it remains unclear if the few mitotic 
DKO NSC are arrested and unable to undergo normal mito-
sis, or if they can achieve a normal mitosis. Some degree of 
mitotic arrest in the DKO NSC is of interest, especially as 
myc overexpression has been associated with G2 arrest [57] 
suggesting myc levels may be particularly important for 
G2/M. Although myc has previously been linked to mito-
sis, that study demonstrated that high levels of myc dis-
rupted normal mitosis [58]. Since myc has been postulated 
to dissociate from chromatin during mitosis [59], it may be 
that during late G2 and early M phases, Myc orchestrates 
a transcriptional program that then normally carries cells 
through mitosis. Alternatively some level of Myc still asso-
ciated with chromatin may directly regulate mitosis during 
mitosis.
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In  terms  of  region-specific  brain  growth,  our  model 
argues that c-, N-, and L-myc have both unique and com-
binatorial roles in directing regional growth of the murine 
brain. For example, L-myc is the prime candidate for the 
myc  family  member  directing  midbrain  growth,  a  func-
tion that may have remained obscured in the constitutive 
L-myc KO mice due to redundancy with or compensation 
by N-myc. Our findings also suggest that myc gene levels 
and expression patterns may contribute to the differences 
in  relative  domain  (fore,  mid,  and  hindbrain  as  well  as 
cerebellar) mass in different species and to brain evolu-
tion.  For example, echolocators, which are unique in that 
their cerebellum consists of approximately 20%, instead 
of the more common 10%, of total brain mass, may have 
higher total myc expression levels or longer periods of myc 
expression during cerebellar development [60]. In addition 
in organisms with a relatively simpler brain structure, one 
might predict less complexity in myc function, and indeed 
in Drosophila Melanogaster, for example, there is only one 
myc gene, dmyc [61]. 
We did not observe any changes in cell survival and no 
clear apoptosis-associated gene expression changes were 
evident in the DKO. Thus, at least c- and N-myc appear 
largely dispensable for NSC survival in vivo. This sharply 
contrasts with HSC, where a dominant phenotype of the 
c-  and  N-myc  DKO  is  apoptosis  manifesting  with  dra-
matic changes in apoptosis-related gene expression [25]. 
Together these findings suggest the intriguing possibility 
that c and N-myc may have fundamentally distinct roles 
in NSC and HSC. Recent murine “placental rescue” [62] 
experiments point to the key role of c-myc in development 
being hematopoiesis, suggesting N-myc plays the primary 
role in development of the embryo itself. Consistent with 
this, mutation of N-myc in humans causes FS with its very 
large range of birth defects in a host of tissues[63]. Interest-
ingly the range of defects in constitutive N-myc KO mice 
are remarkably similar to that of FS [64]. 
It is notable that we observe far more genes upregu-
lated in the DKO brain than downregulated. We have also 
observed this pattern in gene expression studies in cultured 
NSC and in ESC (data not shown) [65]. While myc has 
been shown to have a repressive function through Miz1 
[66], it has always been widely assumed that myc nonethe-
less is predominantly a transcriptional activator. However, 
growing evidence suggests that repression by myc, direct 
and/or indirect, is likely to be equally or more important 
than activation. Consistent with this idea is the notion that 
a key role for myc in iPS cell formation is suppression of 
fibroblast specific gene expression [34]. In iPS cells myc 
appears  to  potently  enhance  reprogramming,  suggesting 
an important role in cell fate. In addition to Miz1, another 
potential mechanism of repression by myc include recruit-
ment of DNMT3A [67].
Enhancing  our  understanding  of  myc  transcriptional 
function during normal development and in normal stem 
cells provides a window into how excess myc may cause 
tumorigenesis, potentially providing additional targets to 
treat  myc-related  tumors.  New  inhibitors  targeting  Myc 
interaction with Max show promise [68], but it may also 
prove fruitful to target functions downstream of Myc such 
as transcriptional or chromatin events as well as cellular 
states maintained by Myc including cellular “stemness”. 
Consistent with this idea, Myc has recently been linked 
with  maintaining  an  aberrant  pluripotent  state  in  tumor 
stem cells including those of glioma [69] and medulloblas-
toma [70, 71]. Forcing changes in chromatin that in turn 
lead to differentiation of cancer cells that have excess Myc 
may be a new method of treatment that does not rely upon 
targeting Myc itself. Future studies on the differences in 
Myc-regulated  chromatin  and  gene  expression  between 
tumor cells and their cognate normal cells of origin should 
shed additional light on tumorigenesis and potential new 
chromatin-based treatments. 
MATERIALS AND METHODS
Animals
The studies involved knockout mice were approved by 
UC Davis IACUC.
Breeding  pairs  of  nestin  Cre-  N-myc(FL/FL)  [22]; 
c-myc(FL/FL) [49] and nestin Cre+ N-myc(FL/WT) c-myc(FL/
FL)    were  set  up  to  generate  the  four  genotypes  Nestin 
Cre- N-myc(FL/FL) c-myc(FL/FL), Nestin Cre- N-myc(FL/WT) 
c-myc(FL/FL), Nestin Cre+ N-myc(FL/FL) c-myc(FL/FL), and 
nestin Cre+ N-myc(FL/WT) c-myc(FL/FL). Genotypes of ani-
mals were determined via PCR using primer sets for Cre, 
N-myc and c-myc. Primer sequences were as follow: Cre1: 
GCC TGC ATT ACC GGT CGA TGC AAC GA; Cre2: 
GTG GCA GAT GGC GCG GCA ACA ACC ATT; N-myc1: 
GTC GCG CTA GTA AGA GCT GAG ATC; N-myc2: GGC 
ACA CAC CTA TAA TCC CAG CTA; N-myc3: CAC AGC 
TCT GGA AGG TGG GAG AAA GTT GAG CGT CTC 
C; c-myc1: GCC CCT GAA TTG CTA GGA AGA CTG; 
c-myc2: CCG ACC GGG TCC GAG TCC CTA TT. Cre1 
and 2 primer sets amplified a 700bp band from Cre inser-
tion. The flox specific band for N-myc1, 2 and 3 primers is 
260bp, the wild-type band is 217bp, and the deletion band 
is 350bp. The flox specific band for c-myc1 and 2 primer 
set is 500bp, and the wild-type band is 400bp. A separate 
primer set to detect c-myc deletion, c-mycDS: TCG CGC 
CCC TGA ATT GCT AGG AA, and c-mycDA: TGC CCA 
GAT AGG GAG CTG TGA TAC TT, were used and ampli-
fies a band at ~750bp.
Immunohisto- and cytochemistry
All E12.5 embryos were immersion-fixed overnight in 
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fresh, buffered 4% paraformaldehyde, paraffin embedded 
and cut (12μm) sagittally. Pregnant female were anesthe-
tized with 150mg/kg ketamine and 16mg/kg xylazine, then 
E17.5 embryos were removed individually and perfused 
with buffered 4% paraformaldehyde. Brains were removed 
and fixed overnight in fresh, buffered 4% paraformalde-
hyde, then cryopreserved and cut (12μm) sagittally. For 
immunostaining,  E12.5  embryo  sections  were  deparaf-
finized then rehydrated and 30mM sodium citrate treated 
for 10 minutes at 95°C, while E17.5 frozen brain sections 
were post fixed in -20°C Acetone for 10 minutes followed 
by three 5 minutes PBS wash. All sections were blocked in 
10% normal goat serum in PBS for 1 hour at room tempera-
ture then incubated in primary antibody overnight at 4°C. 
Antibodies used include anti-BrdU (Chemicon MAB3424, 
1:150), anti-PhosphoH3 (Upstate 06-570, 1:200), and anti-
TubulinßIII (TUJ; Covance PRB-435P, 1:150). The next 
day sections were washed in PBS three times 10 minutes 
each, then incubated in secondary antibody for 2 hours at 
room temperature. Alexa Fluor Goat α Rabbit IgG λ488 
(Invitrogen A11008) and Alexa Fluor Goat α Mouse IgG 
λ546 (Invitrogen A 11003) were used at 1:1000 dilution. 
Sections were washed again in PBS three times 10 min-
utes each, then mounted in Vectashield mounting medium 
with DAPI (VECTOR H-1200). Anti-BrdU staining was 
conducted on embryos from pregnant females who were 
IP injected with BrdU (Sigma B5002, 150μg/g) following 
2-4  hours  BrdU  incorporation  periods. TUNEL  staining 
was performed using the DeadEnd Fluorometric TUNEL 
System Kit (Promega G3250) as directed. 
Microarray and Quantitative Real-Time PCR
Cortex, midbrain and cerebellum were dissected from 
brains  of  freshly  sacrificed  E17.5  embryos.  Total  RNA 
was isolated from these brain areas using RNeasy Mini 
Kit  (Qiagen  74134)  with  DNaseI  digestion  (Invitrogen 
18068-015)  performed  post  RNA  extraction.  Quality  of 
RNA was checked and cRNA was produced by UC Davis 
Gene Expression Analysis facility for hybridization to Sen-
trix Mouse Ref-8 Expression microarray. qPCR was per-
formed on total RNA from the same batch sent off for array. 
Samples were processed using Express SYBR Green qPCR 
Supermix (Invitrogen A10314) according to manufacture 
protocol. All qPCR data were generated using ß-Actin as 
reference  (house-keeping)  gene.  This  gene  was  chosen 
basted on microarray results, which showed no significant 
expression variation between control and double knockout 
brains. Primer efficiency was tested by generating standard 
curves for all primers against each of the 3 brain areas. 
Cycling was conducted as follows: pre-incubation at 95°C 
for 5 minutes, 45 cycles of amplification at 95°C for 10 
seconds, 60°C for 20 seconds, and 72°C for 30 seconds, 
followed by one cycle of melting curve at 95°C for 5 sec-
onds, 65°C for 1 minute and 97°C continuous.
Cell Quantification
Ventricular  zone  of  E12.5  and  E17.5  embryo  cortex 
were mapped out according to comparable Nissl stained 
sections and the mouse brain atlas. Ventricular zone size 
varied depending on size of cortex. Entire ventricular zone 
was divided into ten sections, lengthwise, but only cells in 
the middle eight sections were counted. Total number of 
cells was obtained by counting all the DAPI positive cells. 
Number of BrdU and Phospho H3 cells was obtained by 
counting  the  TRITC  and  FITC,  respectively,  positively 
stained cells. Percentage of BrdU and Phospho H3 cells 
was calculated by dividing the total number of BrdU or 
Phospho H3 cells over the total number of cells in the ven-
tricular zone. Furthermore, for Phospho H3 stained sec-
tions a separate percentage of positively stained cells were 
calculated by combing the subventricular and intermediate 
zone.
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